Pfizer withdraws sickle cell disease treatment on risk of …
WEB2 days ago · Pfizer bought Oxbryta, also known as voxelotor, as part of its $5.4 billion buyout of Global Blood Therapeutics in 2022. It reported $328 million in revenues from the therapy for the full year 2023.
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle ...
WEB1 day ago · Oxbryta was the centerpiece of Pfizer's $5.4 billion buyout of Global Blood Therapeutics in 2022, one of a number of deals bankrolled by the pandemic-era windfall. ... Reuters, the news and media ...
FDA alerts patients about Pfizer's Oxbryta withdrawal
WEB1 day ago · Sept 26 (Reuters) - The U.S. Food and Drug Administration on Thursday alerted patients and healthcare professionals about the withdrawal of Pfizer's (PFE.N) sickle cell disease treatment Oxbryta ...
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease …
WEB2 days ago · NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time ...
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease …
WEB3 days ago · Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide. Pfizer's decision is based on the totality of clinical data that now indicates the ...
Pfizer pulls sickle cell pill Oxbryta over safety concerns - STAT
WEB2 days ago · Sept. 25, 2024. Pfizer said Wednesday that it was removing Oxbryta, a pill for the treatment of sickle cell disease, from all markets globally due to high risks of severe safety events, including ...
Pfizer pulls sickle cell disease therapy Oxbryta from markets
WEB2 days ago · The drug was the centerpiece in Pfizer’s $5.4 billion acquisition of Global Blood Therapeutics in 2022 during a post-COVID M&A spree for the drugmaker. At that time, Pfizer said Oxbryta and GBT ...
Pfizer to pull sickle cell drug from market, shut down trials
WEB2 days ago · Pfizer acquired Oxbryta via its $5.4 billion purchase of Global Blood Therapeutics in 2022. At the time, Pfizer said sales of Oxbryta and two more experimental sickle cell drugs developed by Global Blood could top $3 billion. Oxbryta revenue reached $92 million in the second quarter of this year.
Pfizer Withdraws SCD Drug Oxbryta after EMA Discloses 16 …
WEB1 day ago · Pfizer inherited Oxbryta when it acquired the drug’s original developer, Global Blood Therapeutics (GBT), for $5.4 billion, a deal completed in October 2022. At the time, Pfizer said the deal ...
Pfizer's Oxbryta Exit May Hasten Trials of Rival ... - U.S. News
WEB2 days ago · Oxbryta was the centerpiece of Pfizer's $5.4 billion buyout of Global Blood Therapeutics in 2022, one of a number of deals bankrolled by the pandemic-era windfall. It also picked up two other ...
- Some results have been removed